|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-3.78/-6.35
|
企业价值
653.57M
|
资产负债 |
每股账面净值
14.98
|
现金流量 |
现金流量率
--
|
损益表 |
收益
12.60M
|
每股收益
1.84
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/16 19:39 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates. |